Clinical Roundup: Cardiff, VYNE and NewAmsterdam Report Key Trial Results in Multiple Disease Areas

Cardiff Oncology shared Phase II data for onvansertib plus standard-of-care in first-line RAS-mutated metastatic colorectal cancer, reporting a 64% objective response rate (ORR) at the 30mg dose versus 33% for the standard-of-care alone13.

Deeper tumor regression was observed in the 30mg onvansertib arm, with a safety profile similar to that of the 20mg dose1.

NewAmsterdam Pharma announced that its BROADWAY trial achieved statistically significant reductions in key Alzheimer's disease endpoints23.

The clinical roundup spans three distinct disease areas, though details on VYNE's update were not available in the provided search results3.

Cardiff Oncology recently closed patient enrollment for its Phase II CRDF-004 trial in first-line metastatic colorectal cancer across 41 U.S. clinical sites4.

Sources:

1. https://www.clinicaltrialsarena.com/news/cardiff-oncology-announces-positive-colorectal-data-and-40m-stock-oversubscription/

2. https://ir.newamsterdampharma.com/news-releases/news-release-details/newamsterdam-pharma-presents-positive-data-broadway-trial

3. https://firstwordpharma.com/story/5985035

4. https://investors.cardiffoncology.com/news-releases/news-release-details/cardiff-oncology-reports-second-quarter-2025-results-and